

# Prevalence and Associated Risk Factors of Hepatitis B Virus Infections Among HIV-1 Infected Patients Attending the Comprehensive Care Clinic in Malindi Sub-County Hospital in Kenya

James Gitau Komu<sup>1\*</sup> James Mburu Kangethe<sup>2</sup> Alex Maiyo<sup>3</sup> Juliette Ongus<sup>1</sup> Raphael Lwembe<sup>3</sup>

1.College of Health Sciences, Jomo Kenyatta University of Agriculture and Technology. P.O. Box 62000-0200 Nairobi, Kenya

2.Comprehensive Care Center, Kenyatta National Hospital. P.O. Box 20723-00202, Nairobi, Kenya

3.Center for Virus Research, Kenya Medical Research Institute P.O BOX 54840-00200, Nairobi, Kenya

## Abstract

Human Immunodeficiency Virus (HIV) and Hepatitis B Virus (HBV) co-infections are common all over the world. Infection with HIV increases rates of HBV chronicity, prolong the time the HBV stays in circulation and increase liver-related morbidity. Factors such as intravenous drug use, multiple blood transfusions, presence of tattoos, unsafe sexual practices and being health workers have been implicated as drivers of infection & transmission of HBV & HIV. This study aimed to determine the prevalence and genotypes of HBV associated risk factors among HIV infected patients in a descriptive cross-sectional study. Malindi was chosen as a suitable study site because of the high numbers of residents involved in sex tourism as well as intravenous drug use. A structured questionnaire was used to capture social demographic data such as age, gender, employment status, occupation, the level of education and marital status, clinical history information such as duration since diagnosis with HIV, ART drug history, duration taking ARVs and baseline CD4 count and risk factors associated with HBV infections such as intravenous drug use, history of blood transfusion, tattooing/scarification, and the sexual history from 446 consenting randomly selected HIV infected participants. Five millilitres of whole blood was obtained from each participant, 50µl of which was used for CD4 cell counts using a flow cytometer. HBsAg serology was done using Diaspot® rapid diagnostic test and confirmed by Hepanostika® HBsAg Ultra ELISA kit (BioMérieux SA) and HBV DNA was extracted from all HBsAg positive samples. Nested polymerase chain (PCR) reaction and sequencing of the Pre S1 region was done. Sample sequences were compared with published HBV genotypes sequences from GenBank and Phylogenetic trees were constructed using the NJ Plot software using a PHB file created through DNA Database of Japan (DDBJ) to determine the HBV genotypes. Out of the 446 HIV positive participants, 126 (28.3%) were males and 320 (71.7%) females. Only 19/446 (4.26%) participants were positive for HBV based on rapid strip test while 22/446 (4.93%) participants had HBV based on ELISA. Twelve of the 22 ELISA positive samples were successfully amplified by PCR. Out of the 12 PCR positive samples 10 were successfully sequenced. Phylogenetic analysis revealed that 9/10 (90%) samples belonged to genotype A while 1/10 (10%) belonged to genotype E. Males ( $p=0.028$ ) and intravenous drug use ( $p=0.08$ ) were significantly associated HBV infections. The high prevalence (4.9%) of HBV among HIV patients attending Malindi Sub-county hospital is most likely highly driven by intravenous drug use and multiple sexual partners among the male gender and is predominantly genotypes A and E which is similar to the general population.

**Keywords:** Hepatitis B virus, HIV, Co-infection, HBsAg, genotypes, intravenous drug use

## Introduction

Hepatitis B virus (HBV) and Human Immunodeficiency Virus (HIV) are major public health problems and are among the 10 highest causes of infectious deaths in the world (Alter, 2006). The two viruses share similar routes of transmission (Alter, 2006, Otedo, 2004) with HBV having a hundred fold efficiency in transmission compared to HIV (Otedo, 2004). Individuals with HIV-HBV co-infection have higher HBV DNA levels (Dore *et al.*, 2010) which is associated with the immune deficiency due to HIV which in turn translates to increased HBV disease progression (Diwe *et al.*, 2013). On top of this, increased mortalities and morbidity in HIV patients as a result of liver disease are partly due to co-infection with HBV and HCV since these viruses increase intra-hepatic apoptosis which is a consequence of liver fibrosis (Diwe *et al.*, 2013).

In the world, it's approximated that 33 million people are infected with HIV and among these about 3 million (10%) are co-infected with HBV (Kourtis *et al.*, 2012). In Kenya the prevalence of HBV-HIV co-infection has been reported to be as high as 6% and significantly higher in males 19.2% compared to 14.2% in females in a study done among several Nairobi based health centres. (Muriuki *et al.*, 2013).

HBV has a wide genetic variability which has resulted into the emergence of 10 genotypes with several sub-genotypes which are labelled alphabetically from A-J (Tangkijvanich *et al.*, 2013). There is remarkable evidence suggesting that HBV genetic variability is an important factor in determining disease progression and also response to antiviral treatment (Poukarim *et al.*, 2011). In East Africa where Kenya resides, genotype A is the most

prevalent (88%) followed by genotype E (8%) and then Genotype D (4%) (Mwangi *et al.*, 2008). Webale *et al.* (2015) reported 100% genotype A1 among HIV-1 infected and non-infected injecting and non-injecting drug users in coastal Kenya. Genotype A1 had also been reported exclusively among HIV infected IDUs from Mombasa, a region along the Kenyan coast. (Kibaya *et al.*, 2015)

HBV is more prevalent among HIV-infected individuals than in the general population which can be attributed to the shared risk factors for transmission and acquisition of these two life threatening viruses (Chen *et al.*, 2013). Some of these risk factors associated with the transmission of HIV and HBV include: involvement in intravenous drug use, scarification/tattooing, having several heterosexual partners/involvement in commercial sex, male having sex with men and occupational hazards for health workers (Alter, 2006, Chen *et al.*, 2013, Ranjbar *et al.*, 2013).

The primary aim of this study was to determine the prevalence of HBV and circulating genotypes among HIV positive participants attending the comprehensive care clinic at Malindi Sub-county hospital. The diversity of countries of origin of the tourists to this area and their interaction with the local people would arouse the epidemiological curiosity about the introduction of new strains, their genetic diversity and the implications on the clinical presentation of disease in cases where patients are co-infected. Characterization of HBV among the HIV patients will help in understanding the distribution of specific genotypes in the study setting. The genetic pattern of the virus will in turn help policy makers and clinicians in making sound decisions during prescription of drugs to these patients since different HBV genotypes have different responses to the antiretroviral drugs.

## Methods

### Study site and patients recruitment

This was a descriptive hospital based cross sectional study carried out between May 2015 and April 2017 at the Comprehensive Care Centre (CCC) at the Malindi sub-county hospital. Malindi was selected as a suitable study site because it is located along the coastal strip of Kenya, a region that is popular with tourists both local and foreign. Foreign tourist in Malindi come from all over the world with the Italians, Germans and those from the United Kingdom topping the list. This region is on record for having a fairly large population of persons who engage in sex tourism as well as recreational intravenous substance abuse and in some cases they may share needles to inject themselves with the narcotics and/or engage in unprotected sexual contact. Simple random sampling was used to recruit patients aged 18 years (due to ethical issues) and only those from the CCC. Any vulnerable persons such prisoners and the mentally challenged were not recruited for the study. Participation was upon providing a written informed consent. Those who were randomly selected and did not consent were not recruited and hence replaced.

### Data on socio-demographic, clinical and associated risk factors

A study questionnaire was designed to obtain information from patients and also from the patient's hospital records. The information captured in the questionnaire included: social demographic characteristics including Age, gender, employment status, the level of education and marital status, Clinical history of patients including Duration since diagnosis with HIV, ART drug history, duration taking ARVs and baseline CD4 count. The questionnaire also sought to obtain information on risk factors associated with transmission of HIV and HBV including Intravenous drug use, history of blood transfusion, tattooing/scarification, and the sexual history. The questionnaire was administered in a confidential counselling room by a professional counsellor who was recruited for this study.

### Sample collection, processing, shipping and storage

Five millilitres of blood was collected aseptically into EDTA vacutainer bottles (BD New Jersey, USA) using venepuncture. Fifty microliters (50 $\mu$ l) of the sample were analysed for CD4 counts within 24 hours of collection through flow cytometry using the BD FACS Caliber machine. The samples were then separated using centrifugation at 3000 RPM for 10 minutes and the plasma stored at -20 °C. The samples were then packaged using the basic triple packaging system according to the International Air Transport Association (IATA) regulations. This included primary receptacles (screw capped containers) which were leak proof covered with a layer of absorbent material, a secondary receptacle (zip lock bags) which was also leak proof enclosing the primary receptacle and finally a leak-proof outer packaging i.e. cool box labelled with an easily noticeable biohazard symbol. The samples were then transported to KEMRI under a cold chain through a paid for courier services. After unpackaging they were stored at -80 °C until serological and molecular tests were done.

### HBV serology.

The samples were screened for HBsAg using the DiaSpot® HBsAg test kit which is a rapid one step test for the qualitative detection of HBsAg and Hepanostika® HBsAg Ultra ELISA kit (BioMérieux SA) which is based on a "sandwich" principle. The tests were done according to the manufacturer's instructions.

### DNA extraction and PCR amplification of HBV PRE S1 region

DNA from the 22 samples that tested positive for HBsAg was extracted from 50µl of plasma using Qiagen® DNA extraction kit (Qiagen) using the manufactures instructions. Extracted DNA was used as template in a PCR to amplify the Pre S1 (681bp) region by nested PCR using a set of primers (table1). To describe this briefly, the master mix for the first amplification included 2.5µl of 10x PCR buffer, 2.0µl of 10mM dNTPs, 0.3µl of first set of primer S1F and S1R (Table 1), 1µl Taq polymerase and 5µl of extracted DNA.

**Table 1: Primers used for HBV PCR amplification and sequencing**

| Primers     | Nucleotide position | Sequences              | Expected fragment size region (bp) |
|-------------|---------------------|------------------------|------------------------------------|
| PS1 forward | 55-72               | TCCTGCTGGTGGCTCCAG     | 940                                |
| PS1 Reverse | 995-974             | CGTTGACATACTTTCCAATCAA |                                    |
| PS2 Forward | 155-173             | ACCCTGYRCCGAACATGGA    | 680                                |
| PS2 Reverse | 835-814             | CAACTCCCAATTACATARCCCA |                                    |

The PCR conditions started at 94°C for 7 minutes, followed by 38 cycles of 94°C for 40 seconds, 60°C for 1 minute and 72°C for 2 minutes and final extension for 72°C for 15 minutes. The second master mix will include 5µl of 10x PCR buffer, 1.5µl magnesium chloride, and 4.0µl of dNTPs, 0.25µl of second set of primer S2F and S2R (table 1) and 2µl Taq polymerase. Visualization of amplified DNA was done on 1.2% agarose gel in 1x TAE buffer stained with ethidium bromide.

### Sequencing and viral genotyping

Purified PCR products were directly sequenced using BigDye terminator v3.0 in a Sequencing Ready Reaction Kit (Macrogen Inc, Korea) using the 2<sup>nd</sup> PCR primers S2F and S2R (table 1). The sequencing reactions were performed using ABI3730 automated sequencer (Applied Bio systems). The resulting forward and reverse sequences from each sample were assembled using the GENETYX® Ver.9 software. The sequences were aligned with references sequences from gene bank and trimmed with MEGA 7.0.25 software. Phylogenetic relationship were inferred by creating a PHB file through the DNA Data bank of Japan (DDBJ) and opening the file through NJ plot software.

### Ethical consideration

The study was ethically approved by the KEMRI scientific steering committee (SSC) and the Ethical review committee (ERC) (SSC Protocol number 2913) before implementation. The study was also approved by the Kilifi County Research committee (Ref:DOH/KLF/RESCH/VOL.I/21) and the management of Malindi Sub-county Hospital.

### Data analysis

Social demographic, clinical and risk factors data was entered and cleaned using Ms Excel and transferred to Statistical package for social sciences (SPSS) version 21. SPSS was used to analyse the frequencies, means and percentages for the social demographic data, clinical data and the risk factors against the HBV sero-positivity through cross-tabulation. Independent t test was used for comparison of means for the CD4 counts between the HIV mono-infected and HIV-HBV mono-infected. STATA was used to perform bivariate and multivariate analysis to determine factors associated with HBV infections using Poisson regression with significance set at  $P \leq 0.05$  and odds ratio with corresponding 95% confidence interval.

## Results

### Baseline characteristics of study participants

A total of 446 HIV positive participants including 126 (28.3%) males and 321(71.8%) females were enrolled for the study. Their ages ranged from 18-76 years with a mean age of 42.98 +/-10.750 years. The mean age of males was 44.93 years (SD ±10.16) while that of females was 42.22 years (SD ±10.88). Other baseline characteristics of the study participants have been summarised in table 2

At the time of sample collection 69 (15.5%) individuals had not started ARVS. Those who were taking AZT, 3TC, NVP regimen were the majority (33.4%) while 26.9% were on 3TC, TDF, EFV. The rest (24.2%) were on TDF, 3TC, NVP

**Table 2- Baseline characteristics among HIV positive patients attending Malindi sub-county Hospital**

| Variable                                       | Sample size (N = 446) |                  |
|--|-----------------------|------------------|
|  | No                    | %                |
| <b>Age (Years)</b>                             |                       |                  |
| Mean ( $\pm$ SD)                               | 42.98                 | ( $\pm$ 10.75)   |
| Median (IQR)                                   | 43                    | (34.75 - 50)     |
| Range  | 58                    | (18 - 76)        |
| $\leq$ 30                                      | 62                    | 13.9             |
| 31-40  | 125                   | 28.1             |
| 41-50  | 158                   | 35.4             |
| $\geq$ 50                                      | 101                   | 22.6             |
| <b>Gender</b>                                  |                       |                  |
| Males  | 126                   | 28.3             |
| Females  | 320                   | 71.7             |
| <b>Level of Education</b>                      |                       |                  |
| Primary  | 240                   | 53.8             |
| Secondary                                      | 77                    | 17.3             |
| Tertiary                                       | 21                    | 4.7              |
| none   | 108                   | 24.2             |
| <b>Employment status</b>                       |                       |                  |
| employed/self employed                         | 246                   | 55.2             |
| unemployed                                     | 200                   | 44.8             |
| <b>Marital status</b>                          |                       |                  |
| Single   | 48                    | 11               |
| Married  | 236                   | 53               |
| widow/divorced                                 | 162                   | 36               |
| <b>ARV drug currently on use</b>               |                       |                  |
| 3TC, TDF, EFV                                  | 120.0                 | 26.9             |
| AZT, 3TC, NVP                                  | 149                   | 33.4             |
| TDF,3TC, NVP                                   | 108                   | 24.2             |
| Not started                                    | 69                    | 15.5             |
| <b>CD4 count</b>                               |                       |                  |
| Mean ( $\pm$ SD)                               | 417.49.               | ( $\pm$ 239.643) |
| Median (IQR)                                   | 403.5                 | (247.5-562)      |
| Range  | 1331                  | 0-1331           |
| CD4 less 500                                   | 292                   | 65.5             |
| CD4 $\geq$ 500                                 | 154                   | 34.5             |
| <b>Duration Since HIV diagnosis</b>            |                       |                  |
| 0-5 yrs  | 227                   | 50.9             |
| 6-10 yrs                                       | 204                   | 45.7             |
| >10yrs   | 13                    | 3.4              |
| <b>Duration since ART initiation</b>           |                       |                  |
| 0-5 yrs  | 264                   | 59.2             |
| 6-10 yrs                                       | 175                   | 39.2             |
| >10yrs   | 7                     | 1.6              |
| <b>Intravenous Drug Use</b>                    |                       |                  |
| Yes  | 13                    | 2.7              |
| no   | 433                   | 97.3             |
| <b>History of blood transfusion</b>            |                       |                  |
| Yes  | 36                    | 8.1              |
| No   | 410                   | 91.9             |
| <b>Scarification/Tattooing</b>                 |                       |                  |
| Yes  | 9                     | 2                |
| No   | 437                   | 98               |
| <b>Involvement in CSW</b>                      |                       |                  |
| Yes  | 23                    | 5.2              |
| No   | 423                   | 94.8             |
| <b>Sexuality</b>                               |                       |                  |
| Heterosexual                                   | 441                   | 98.9             |
| Homosexual/Bisexual                            | 5                     | 1.1              |
| <b>Number of partners in the past 6 months</b> |                       |                  |
| None   | 86                    | 19.3             |
| One  | 329                   | 73.8             |
| 2 to 3   | 24                    | 5.4              |
| $\geq$ 4                                       | 7                     | 1.6              |

### Laboratory results

A total of 19 (4.26%) participants were HBsAg positive based on rapid strip test while 22 (4.94%) participants were positive for HBsAg based on ELISA. All the 19 samples that were positive via the rapid test were confirmed positive via ELISA. Males had the highest prevalence of the HIV-HBV co-infection 11 out of 126 (8.7%) compared to 11 out of 320 females (3.4%). HBV DNA was successfully amplified in 12 out of 22 (54.5%) samples positive for HBsAg ELISA. 10 out of the 12 HBV-DNA positive samples were successfully sequenced. This has been summarised in table 3

**Table 3: A summary of the laboratory tests done and their results**

|          | HBsAg serology (n=446) |              | HBV DNA PCR positive (n=22) | HBV Sequencing (n=12) |
|----------|------------------------|--------------|-----------------------------|-----------------------|
|          | Rapid                  | ELISA        |                             |                       |
| Positive | 19 (4.26%)             | 22 (4.94%)   | 12 (54.5%)                  | 10 (83.3%)            |
| Negative | 427 (95.74%)           | 424 (95.06%) | 10 (45.5%)                  | 2 (16.7%)             |

The mean CD4 count for the study population was 417.5 (SD = ±240.3 cell/μl). Although not statistically significant (p = 0.429) those who were HIV-HBV co-infected had a lower CD4 count (378 cell/μl) compared to those who were HIV mono-infected (419.5 cell/μl)..

### Phylogenetic analysis and genotypes

Phylogenetic analysis revealed that 9/10 (90%) belonged to genotype A which were all categorised into sub-genotype A1 while 1/10 (10%) belonged to genotype E. A phylogenetic tree was constructed by NJ plot software using a phb file generated from DNA Data Bank of Japan (DDBJ) as shown in fig 1.




Fig 1: Phylogenetic analysis based on the Pre-S region from 10 HBV strains from HBV-HIV co-infected patients attending the Malindi Sub-County Hospital and selected reference sequences representing some of the known HBV genotypes/Sub-genotypes from the Genebank. The 10 HBV characterised in this study are indicated in bold and 9/10 fall under genotype A1 while 1/10 fall under Genotype E. The references are labelled with their accession numbers, country of origin and the genotype they belong to. The tree is rooted from the Woolley Monkey virus genome sequence.

### Factors associated with HBV infections

Univariate analysis showed that gender ( $p = 0.029$ ) and Intravenous drug use ( $p = 0.008$ ) were significantly associated with HBV infection whereas all other factors were not statistically significant. In Multivariate analysis gender ( $p = 0.013$ ) and Intravenous drug use ( $p = 0.05$ ) were also statistically significant (Table 4)

**Table 4: Univariate and Multivariate analysis of factors associated with HBV infection among HIV patients attending CCC at Malindi Sub-County Hospital. (N=446)**

| Variable                                 | Sample size (N = 446) |                |       | P - value    | Bivariate            |              | Multivariate         |  |
|--|-----------------------|----------------|-------|--------------|----------------------|--------------|----------------------|--|
|  | No.                   | HBV No. (n=22) | HBV % |              | OR (95% CI)          | P - value    | OR (95% CI)          |  |
| <b>Gender</b>                            |                       |                |       |              |                      |              |                      |  |
| Male                                     | 126                   | 11             | 8.7   | <b>0.029</b> | <b>2.2(1.1-5.9)</b>  | <b>0.013</b> | <b>3.2(1.3-8.1)</b>  |  |
| Female                                   | 320                   | 11             | 3.4   | Referent     | Referent             | Referent     | Referent             |  |
| <b>Age (Years)</b>                       |                       |                |       |              |                      |              |                      |  |
| ≤30                                      | 62                    | 2              | 3.2   | 0.34         | 0.5(0.1-2.2)         | 0.542        | 0.6(0.1-3.0)         |  |
| 31-40                                    | 125                   | 4              | 3.2   | 0.218        | 0.5(0.1-1.5)         | 0.384        | 0.6(0.2-2.0)         |  |
| 41-50                                    | 158                   | 9              | 5.7   | 0.697        | 0.8(0.3-2.2)         | 0.961        | 1.0(0.4-2.7)         |  |
| >50                                      | 101                   | 7              | 6.9   | Referent     | Referent             | Referent     | Referent             |  |
| <b>Employment status</b>                 |                       |                |       |              |                      |              |                      |  |
| employed/self employed                   | 246                   | 14             | 5.7   | 0.426        | 1.4(0.6-3.4)         | 0.378        | 1.5(0.6-3.8)         |  |
| unemployed                               | 200                   | 8              | 4     | Referent     | Referent             | Referent     | Referent             |  |
| <b>Level of Education</b>                |                       |                |       |              |                      |              |                      |  |
| Primary                                  | 240                   | 14             | 5.6   | 0.92         | 1.1(0.4-2.7)         | 0.606        | 0.8(0.3-2.2)         |  |
| Secondary                                | 77                    | 1              | 1.3   | 0.178        | 0.2(0-1.9)           | 0.056        | 0.1(0-1)             |  |
| Tertiary                                 | 21                    | 1              | 4.8   | 0.887        | 0.9(0.1-7.1)         | 0.511        | 0.5(0.1-4.3)         |  |
| Non formal                               | 108                   | 6              | 5.6   | Referent     | Referent             | Referent     | Referent             |  |
| <b>Marital status</b>                    |                       |                |       |              |                      |              |                      |  |
| Single                                   | 48                    | 1              | 2.1   | 0.352        | 0.4(0.0-3.0)         | 0.532        | 0.5(0.1-4.2)         |  |
| Married                                  | 236                   | 12             | 5.1   | 0.841        | 0.9(0.4-2.1)         | 0.514        | 0.7(0.3-1.8)         |  |
| Widow/Widower/Divorced                   | 162                   | 9              | 5.6   | Referent     | Referent             | Referent     | Referent             |  |
| <b>ARV drug currently on use</b>         |                       |                |       |              |                      |              |                      |  |
| 3TC, TDF, EFV                            | 120.0                 | 8              | 6.7   | 0.15         | 4.6(0.6-36.8)        | 0.995        | 0                    |  |
| AZT, 3TC, NVP                            | 149                   | 10             | 6.7   | 0.144        | 4.6(0.6-36.2)        | 0.995        | 0                    |  |
| TDF,3TC, NVP                             | 108                   | 3              | 2.8   | 0.573        | 1.9(0.2-18.4)        | 0.995        | 0                    |  |
| Not started                              | 69                    | 1              | 1.4   | Referent     | Referent             | Referent     | Referent             |  |
| <b>CD4 count</b>                         |                       |                |       |              |                      |              |                      |  |
| Less than 500                            | 292                   | 16             | 5.5   | 0.476        | 1.4(0.6-3.6)         | 0.433        | 1.5(0.6-3.9)         |  |
| Greater than 500                         | 154                   | 6              | 3.9   | Referent     | Referent             | Referent     | Referent             |  |
| <b>Duration since HIV diagnosis</b>      |                       |                |       |              |                      |              |                      |  |
| 0-5yrs                                   | 227                   | 9              | 4     | 0.995        | 0                    | 1            | 0                    |  |
| 6-10yrs                                  | 204                   | 13             | 6.4   | 0.965        | 0                    | 1            | 0                    |  |
| >10yrs                                   | 15                    | 0              | 0     | Referent     | Referent             | Referent     | Referent             |  |
| <b>Duration since ARV initiation</b>     |                       |                |       |              |                      |              |                      |  |
| 0-5yrs                                   | 264                   | 11             | 4.2   | 0.996        | 0                    | 0.999        | 0                    |  |
| 6-10yrs                                  | 175                   | 11             | 6.3   | 0.996        | 0                    | 0.999        | 0                    |  |
| >10yrs                                   | 7                     | 0              | 0     | Referent     | Referent             | Referent     | Referent             |  |
| <b>Intravenous drug use</b>              |                       |                |       |              |                      |              |                      |  |
| Yes                                      | 13                    | 3              | 23.1  | <b>0.008</b> | <b>5.3(1.6-17.8)</b> | <b>0.05</b>  | <b>4.1(1.0-16.6)</b> |  |
| no                                       | 433                   | 19             | 4.4   | Referent     | Referent             | Referent     | Referent             |  |
| <b>History of blood transfusion</b>      |                       |                |       |              |                      |              |                      |  |
| Yes                                      | 36                    | 0              | 0     | 1            | 0                    | 0.995        | 0                    |  |
| No                                       | 410                   | 22             | 5.4   | Referent     | Referent             | Referent     | Referent             |  |
| <b>Scarification/Tattooing</b>           |                       |                |       |              |                      |              |                      |  |
| Yes                                      | 9                     | 0              | 0     | 0.999        | 0                    | 0.997        | 0                    |  |
| No                                       | 437                   | 22             | 5     | Referent     | Referent             | Referent     | Referent             |  |
| <b>CSW</b>                               |                       |                |       |              |                      |              |                      |  |
| Yes                                      | 23                    | 1              | 4.3   | 0.897        | 0.9(0.1-6.5)         | 0.813        | 0.8(0.1-6.0)         |  |
| No                                       | 423                   | 21             | 5     | Referent     | Referent             | Referent     | Referent             |  |
| <b>Sexuality</b>                         |                       |                |       |              |                      |              |                      |  |
| Homosexual                               | 1                     | 0              | 0     | 1            | 0                    | 0.999        | 0                    |  |
| Bisexual                                 | 4                     | 0              | 0     | 1            | 0                    | 0.998        | 0                    |  |
| Heterosexual                             | 441                   | 22             | 5     | Referent     | Referent             | Referent     | Referent             |  |
| <b>No. of patners in past six months</b> |                       |                |       |              |                      |              |                      |  |
| One                                      | 329                   | 14             | 4.3   | 0.161        | 0.5(0.2-1.3)         | 0.398        | 0.7(0.2-1.7)         |  |
| 2 to 3                                   | 24                    | 1              | 4.2   | 0.531        | 0.5(0.1-4.2)         | 0.846        | 0.8(0.1-8.8)         |  |
| ≥4                                       | 7                     | 0              | 0     | 0.994        | 0                    | 0.998        | 0                    |  |
| None                                     | 86                    | 7              | 8.1   | Referent     | Referent             | Referent     | Referent             |  |

### Discussion

Several studies have been carried out in Sub-Saharan Africa including Kenya to access the burden of hepatitis B virus among HIV infected individuals. However majority of this studies focus on populations that form risk sub-

populations for HIV and HBV transmission or newly diagnosed HIV patients. The present study focused prevalence, risk factors and genotypes of HBV in a generalized HIV infected patients population receiving medical care in one of government hospital set up in Kilifi County.

Generally, the prevalence of HBV is higher among HIV-infected individuals than in the general population which can be attributed to the shared risk factors for transmission and acquisition of these two life threatening viruses (Chun *et al.*, 2012). The present study reported a HBV prevalence of 4.9% (22/446) among HIV positive participants based on laboratory analysis of HBsAg through ELISA. The rates of HIV-HBV co-infections have previously been reported to be as high as 10–20% in countries where HBV infection is either endemic or intermediate to high HBV cases (Muriuki *et al.*, 2013). In Kenya, a study by Muriuki *et al.*, 2013 on the prevalence of HBV and HIV co-infection showed a prevalence of 6% with co-infection rates significantly higher among males (19.2%) compared to females (14.3%). This result was also in agreement with other studies carried out in Kenya including; 5.7% (Wambani *et al.*, 2015), 4.26 % (Kerubo *et al.*, 2015) and 3.6 % as reported by Webale *et al.*, (2015) among HIV positive non-IDUs in Mombasa, Coastal Kenya. The results were also similar to those reported in other parts of the world including 5.2 % in Morocco (Rebbani *et al.*, 2013) and 3.8 % in Brazil (Brandaoa *et al.*, 2015). In South Africa between 5% and 17% of HIV-infected patients in the country were found to be co-infected with Hepatitis B virus (Chun *et al.*, 2012).

The results of this study were found to be lower than those of other studies carried out in other studies including jaundiced patients in Kenya which reported 53 % (Otedo, 2004) and 50.6 % (Ochwoto *et al.*, 2016), 25.5 % among HIV patients in Morocco (Magoro *et al.*, 2016), 19.2 % among HAART naïve patients in China (Chen *et al.*, 2013), 12 % among HIV patients in Columbia (Bautista *et al.*, 2014), 10.5 % among HIV patients in Lesotho (Mugomeri *et al.*, 2015), 9.6 % among HIV IDUs in Mombasa, Kenya (Webale *et al.*, 2015). The higher HBV prevalence rates in this studies compare to the current study could have been as a result of using sub-populations that have evident signs associated with HBV such as the jaundiced patients who were attending clinics due to liver related complication, being selected from HBV high risk sub-populations such as the intravenous drug users or newly diagnosed patients who had not started ART.

On the other hand, the results reported in this study were contrarily higher compared to reports from Nigeria as reported by Dore *et al.*, (2010) and Diwe *et al.*, (2013) indicating HBV/HIV prevalence rates of 2.4% and 2.2% respectively, 2.2 % in Malawi (Varo *et al.*, 2016) and 2.5 % in Brazil (Freitas *et al.*, 2014). The higher prevalence rate in the present study could be as a result the samples being collected from a HBV prevalence intermediate (2-7%) area as classified by WHO (Zenebe *et al.*, 2014). As reported by Mukami *et al.*, (2013) other factors that might have resulted in disparities in the prevalence rates between this studies result and those conducted in other places could include but not limited to sample size used, specificity and sensitivity of kits used and diversity of behavioural characteristics of each population.

Phylogenetic analysis of the HBV genotypes in the current study revealed the presence of genotype A (90%) and E (10%) as would be expected of the Kenyan population. This observation is in agreement with other studies done in Kenya that reported a prevalence of 88% (Mwangi *et al.*, 2008), 90.3 % (Ochwoto *et al.*, 2016), 100 % (Webale *et al.*, 2015) of genotype A1. Mwangi *et al.*, (2008) had also reported genotype E although at a much lower prevalence than genotype A. All the genotype A sequences belonged to the HBV genotype A1 sub-genotypes. Five of the genotype A and the genotype E sequences clustered with sequences from countries in sub Saharan Africa including Tanzania, central Africa republic, South Africa Ivory coast and Guinea. This could be attributed to trade relationships between these African countries. The rest four sub-genotype A1 samples clustered with samples from Somalia and the Asian clade (Phillipines and Japan). This could be as a result of immigrants from Somalia who access the Kenyan coast and tourists from the Asian countries.

The current study looked for association between the social demographic, clinical history and risk/behavioral factors with HBV among HIV positive participants. Male gender was found to be significantly associated with HBV infection among the HIV positive participants. This finding agrees to other studies carried out in Lesotho, Brazil and Nigeria (Mugomeri *et al.*, 2015, Freitas *et al.*, 2014, Balogun *et al.*, 2012). Contrary to the findings of this study, Kerubo *et al.*, (2014) in a study involving participants from two informal settlements in Nairobi, Kenya did not find any association between HIV/HBV co-infection with gender. The fact that male gender is associated with HBV in the current study can be attributed to risky behaviours related to HBV transmission such as multiple sexual partners without use of protective measures and involvement in intravenous drug use more than their female counterparts.

Involvement in intravenous drug use was also found to be significantly associated with HBV infection OR, 5.3 (95% CI 1.6-17.8) among HIV participants of this study. Zenebe *et al.*, (2014) reported that individuals who used injectable drugs were 5 times more likely to have HBV infections which is in tandem with the current study. This is a clear evidence of the efficiency of intravenous drug use in transmission of blood borne viral infections. Other studies have documented that factors such as increasing age (Freitas *et al.*, 2014), blood transfusion (Zenebe *et al.*, 2014, Alhurajji *et al.*, 2014) tattooing/scarification (Zenebe *et al.*, 2014) homosexuality (Freitas *et al.*, 2014, Brandaoa *et al.*, 2015) to be associated with HBV infections among HIV positive patients. This did not however

agree with the present study findings probably due to low numbers of participants who had the above characteristics.

Some of the limitations of this study included the use of a single serological marker. Not all serological markers of HBV were used to for diagnosis of HBV therefore chances of leaving out possible occult cases positive for HBV DNA extraction. In the risk factors analysis, majority of participants who are at higher risk of HBV acquisition such as the known men who have sex with men and intravenous drug users could not participate in the study as they have their special clinics where they receive similar services as those offered in the comprehensive care centre where this study was done. Finally the current study was not able to analyse liver function enzymes (Aspartate transferase and Alanine transaminase) and viral load which would have shown relationship between HBV infection and clinical variables among those who are HIV-HBV co-infected.

### Conclusion

The high HBV-HIV prevalence of 4.9 % among patients attending Malindi Sub-county hospital Comprehensive Care Centre is most likely driven by intravenous drug use and multiple sexual partners among the male gender. Genotype A was the most prevalent 9/10 (90%) while 1/10 (10%) belonged to genotype E an observation that relates well with the distribution of HBV genotypes among the Kenyan general population. There is therefore need to routinely diagnose HBV among new comprehensive care centres recruits to ensure proper therapeutic management using antiretroviral drugs.

### Acknowledgments

We would like to acknowledge the Kilifi county government, department of health sciences and the Malindi sub-county Hospital for granting us permission to carry out the research in the region and Kenya Medical Research Institute, Centre for virus research for provision of laboratory facilities where sample analysis was done.

### References

- Alhurajji, A., Alaraj, A., Alghamdi, S., Alrbiaan, A., & Alrajhi, A. A. (2014). Viral hepatitis B and C in HIV-infected patients in Saudi Arabia. *Annals of Saudi medicine*, 34(3), 207.
- Alter, M.J. (2006). Epidemiology of viral hepatitis and HIV co-infection. *Journal of hepatology*, 44: S6–9.
- Balogun, T.M., Emmanuel, S., Ojerinde, F.E. (2012). HIV, Hepatitis B and C viruses' co-infection among patients in a Nigerian tertiary hospital. *Pan Africa medical journal* 12:100
- Bautista-Amorocho, H., Castellanos-Domínguez, Y.Z., Rodríguez-Villamizar, L.A., Velandia-Cruz, S.A., Becerra-Peña, J.A., Farfán-García, A.E. (2014). Epidemiology, risk factors and genotypes of HBV in HIV-infected patients in the northeast region of Colombia: High prevalence of occult hepatitis B and F3 subgenotype dominance *PLoS ONE* 9(12): e114272.
- Brandão, A.A., Pfrimerb, A.H., Martellia, M.T., Turchi, M.D. (2015). Prevalence of hepatitis B and C infection and associated factors in people living with HIV in Midwestern Brazil. *The Brazilian journal of infectious diseases*. 19(4):426–430
- Chen, X., He, J.M., Ding, L., Zhang, G., Zou, X., Zheng, J. (2013). Prevalence of hepatitis B virus and hepatitis C virus in patients with human immunodeficiency virus infection in Central China. *Archives of Virology* 158:1889–1894
- Chun, H.M., Roediger, M.P., Hullsiek, K.H., Thio, C.L., Agan, B.K., Bradley, W.P., Peel, S.A., Jagodzinski, L.L., Weintrob, A.C., Ganesan, A., Wortmann, G., Crum-Cianflone, N.F., Maguire, J.D., Landrum, M.L. (2012). Hepatitis B virus co-infection negatively impacts HIV outcomes in HIV seroconverters. *The Journal of infectious diseases*, 205(2): pp.185–93.
- Diwe, C.K., Okwara, E.C., Enwere, O.O., Azike, J.E., Nwaimo, N.C. (2013). Sero-prevalence of hepatitis B virus and hepatitis C virus among HIV patients in a suburban University Teaching Hospital in South-East Nigeria. *Pan African Medical Journal*, 16, pp.1–5.
- Dore, G.J., Soriano, V., Rockstroh, J., Kupfer, B., Tedaldi, E., Peters, L., Neuhaus, J., Puoti, M., Klein, M.B., Mocroft, A., Clotet, B., Lundgren, J. D. (2010). Frequent hepatitis B virus (HBV) rebound among HIV – HBV co-infected patients following antiretroviral therapy interruption in the SMART study. *NIH Public Access*, 24(6): 857–865.
- Freitas, S.Z., Soares, C.C., Tanaka, T.S.O., Lindenberg, A.S.C., Teles, S.A., Torres, M.S., Mello, F.C.A., Mendes-Correa M.S., Savassi-Ribas, F., Motta-Castro, A.R.C. (2014). Prevalence, risk factors and genotypes of hepatitis B infection among HIV-infected patients in the State of MS, Central Brazil. *Brazilian journal of infectious diseases* 18(5):473–480
- Kerubo G., Khamadi S., Okoth V., Madise N., Ezeh A., Abdalla Z., Mwau M. (2015). Hepatitis B, Hepatitis C and HIV-1 co-infection in two informal urban settlements in Nairobi Kenya *PLOS ONE* 10(6):e0129247
- Kourtis A.P., Buttery, M., Hu, D.J., Jamieson D.J (2012) HIV-HBV co-infection - A Global Challenge. *The New England Journal of Medicine*, 366:19 (Article was updated on November 2013 at NEJM.org)



- Magoro, T., Gachara, G., Mavhandu, L., Lum, E., Kimbi, H.K., Ndip, R.N., Bessong, P. (2016). Serologic and genotypic characterization of hepatitis B virus in HIV-1 infected patients from South West and Littoral Regions of Cameroon. *Virology Journal* 13(1), 178
- Mugomeri, E., Senauoane, M.B., Ruhanya, V., Chin'ombe, N., Nyandoro, G (2015). Occurrence of HBV/HIV co-infection by laboratory values in Roma, Lesotho. *Germs* 5(1).
- Muriuki, B.M., Gicheru, M.M., Wachira, D., Nyamache, A.K., Khamadi, S.A. (2013). Prevalence of hepatitis B and C viral co-infections among HIV-1 infected individuals in Nairobi, Kenya. *BMC research notes*, 6(1):363.
- Mwangi, J., Nganga, Z., Songok, E., Kinyua, J., Lagat, N., Muriuki, J., Lihana, R., Khamadi, S., Osman, S., Lwembe, R., Kiptoo, M., Mwau, M., Chirchir, R., Mpoke, S., Nyamongo, J., Okoth, F., Yamada, R., Kageyama, S., Ichimura, H. (2008). Molecular genetic diversity of hepatitis B virus in Kenya. *Intervirology* 51(6):417-21
- Ochwoto, M., Kimotho, J.H., Oyugi, J., Okoth, F., Kioko, H., Simeon, M., Budambula, N.L.M., Giles, E., Andonov, A., Songok, E., Osiowy, C. (2016). Hepatitis B infection is highly prevalent among patients presenting with jaundice in Kenya. *BMC infectious diseases* (2016) 16:101
- Otedo A.E. (2004). HBV, HIV Co-infection at Kisumu district hospital, Kenya; *East Africa Medical Journal*; 81(12): 627-630.
- Pourkarim, M.R., Lemey, P., Amini-bavil-olyaee, S., Houspie, L., Verbeeck, J., Rahman, M., Maes, P., Vanwijngaerden, E., Nevens, F., Ranst, M. V. (2011). Molecular Characterization of Hepatitis B Virus Strains Circulating in Belgian Patients Co-Infected With HIV and HBV : Overt and Occult Infection. *Journal of Medical Virology*, 83:1876–1884.
- Ranjbar, R., Davari, A., Izadi, M., Jonaidi, N., Alavian, S M. (2011). HIV/HBV Co-Infections: Epidemiology, Natural History, and Treatment: A Review Article. *Iranian Red Crescent medical journal*, 13(12):855–62.
- Rebbani, K., Ouladlalsen, A., Bensghir, A., Akil, A., Lamdini, H., Issouf, H., Brahim, I., Kitab, B., Fakhir, F. Z., Wakrim, L., Marhoum El Filali, K., Himmich, H., Ezzikouri, S., Benjelloun, S. (2013). Co-infections with hepatitis B and C viruses in human immunodeficiency virus-infected patients in Morocco. *Clinical Microbiology and Infection* 19: E454–E457
- Tangkijvanich, P., Sa-nguanmoo, P., Avihingsanon, A., Ruxrungtham, K., Poovorawan, K., Poovorawan, Y. (2013). Characterization of Hepatitis B Virus Mutations in Untreated Patients Co-Infected With HIV and HBV Based on Complete Genome Sequencing. *Journal of Medical Virology*, 85:16–25.
- Varo, R., Chris Buck, W., Kazembe, P.N., Phiri, S., Andrianarimanana, D., Weigel, R. (2016). Seroprevalence of CMV, HSV-2 and HBV among HIV-Infected Malawian Children: A Cross-sectional Survey *Journal of tropical pediatrics* 62(2):220-226
- Wambani, R.J., Ogola, P.E., Makori, A.W., Nyamai, D.W., Lihana R., Burugu M.W. (2015) Hepatitis B and C Co-Infections among HIV-1 Infected Patients Attending the Academic Model Providing Access to Healthcare Clinic , Kenya. *Journal of infectious diseases & diagnosis* 1(1)
- Webale, M.K., Budambula V., Lihana, R., Musumba F.O., Nyamache, A.K., Budambula, N.L.M., Ahmed, A., Ouma, C., Were, T (2015). Hepatitis B virus sero-profiles and genotypes in HIV-1 infected and uninfected injection and Non-injection drug users from coastal Kenya. *BMC infectious diseases* 15:299
- Zenebe, Y., Mulu, W., Yimer, M., & Abera, B. (2014). Sero-prevalence and risk factors of hepatitis B virus and human immunodeficiency virus infection among pregnant women in Bahir Dar city, Northwest Ethiopia: a cross sectional study. *BMC infectious diseases*, 14(1), 118.